pentobarbital will lower the extent or impact of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital decreases levels of panobinostat by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potent CYP3A4 inducers can decrease panobinostat stages by ~70% and cause procedure failure.
Slight (1)pentobarbital will minimize the extent or influence of paclitaxel protein sure by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.
pentobarbital will minimize the level or result of fosamprenavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
Psychological, tolerance and physical dependence could arise with ongoing use; patients with psychological dependence on barbiturates might produce a Actual physical dependence on barbiturates by growing or reducing the dosage interval without consulting a medical doctor
pentobarbital will lessen the extent or influence of doxorubicin liposomal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital and olopatadine intranasal both equally increase sedation. Keep away from or Use Alternate Drug. Coadministration increases danger of CNS despair, which can result in additive impairment of psychomotor efficiency and induce daytime impairment.
pentobarbital will reduce the level or outcome of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
benzhydrocodone/acetaminophen and pentobarbital equally increase sedation. Keep away from or Use Alternate Drug. Restrict use to patients for whom choice treatment alternatives are insufficient
pentobarbital will reduce the extent or influence of rabeprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.
pentobarbital will lower the level or impact of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will decrease the extent or impact of fentanyl intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to the lower in fentanyl plasma concentrations, insufficient efficacy or, perhaps, improvement of the withdrawal syndrome inside a client who may have produced physical dependence to fentanyl.
pentobarbital will lower the extent or result of isavuconazonium sulfate by check here impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lessen the level or effect of itraconazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Not known.